StockIQpro
NASDAQ:BOLD

Boundless Bio, Inc.

Track all markets on TradingView
Track all markets on TradingView

Boundless Bio, Inc. reported net income of −$58.2M in fiscal 2025. Free cash flow was −$47.2M, and the diluted share count rose 31.7%.Summary generated from Boundless Bio, Inc.'s SEC filings. Latest annual report filed Mar 9, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−46.7%
Debt / equityn/a
Free cash flow−$47.2M
FCF marginn/a
Share count change+31.7%

Financials

Fiscal years, $M
Item202320242025
Revenuen/an/an/a
Operating income−55−73−64
Net income−49−65−58
Free cash flow−47−63−47

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations